MDMA – Multidisciplinary Association for Psychedelic Studies – MAPS
MDMA treatment manual, Investigator’s Brochure (IB), Developmental Safety Update Report (DSUR), accounts of healing, and other important resources and information on MDMA. PTSD is a chronic, debilitating mental health disorder that occurs following a traumatic event.
Phase 3 Trial Program: MDMA-Assisted Therapy for PTSD ...
Studies MAPP1 and MAPP2 are randomized, double-blind, placebo-controlled, multi-site clinical trials that assess the safety and efficacy of MDMA-assisted therapy in 200-300 participants with severe posttraumatic stress disorder (PTSD) from any cause, aged 18 and older.
MDMA-Assisted Therapy for PTSD – Multidisciplinary …
Aug 29, 2024 · MDMA is capable of inducing unique psychopharmacological effects, such as: MAPS recently completed MAPP2, the second of two Phase 3 trials to support FDA approval of this Breakthrough-Designated therapy. With this completion, MDMA-assisted therapy is expected to receive FDA evaluation in 2023.
MAPS | Bessel van der Kolk, MD.
Completion of the MDMA Therapy Training Program course; Experiential Elective; Consultation and Clinical Experience: 40 hours of Clinical Experience providing MDMA-assisted therapy and 15 hours of Consultation; Learn more about MAPS Certification here: https://mapspublicbenefit.com/training/requirements/ This 14-week online program includes:
Multidisciplinary Association for Psychedelic Studies
The Multidisciplinary Association for Psychedelic Studies (MAPS) is an American nonprofit organization working to raise awareness and understanding of psychedelic substances. MAPS was founded in 1986 by Rick Doblin and is now based in San Jose, California.
MDMA-assisted psychotherapy for the treatment of PTSD is to enable the patient to restructure his/her intrapsychic realities and develop a wider behavioral and emotional repertoire with which to respond to anxiogenic stimuli.
MAPS Applies For FDA Approval Of MDMA-Assisted Therapy For PTSD - Forbes
Dec 15, 2023 · MAPS Public Benefit Corporation (MAPS PBC) announced Wednesday that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for MDMA-assisted therapy.
First ever drug application for MDMA finally reaches FDA - Fierce …
Dec 13, 2023 · MAPS' application largely centers around two phase 3 studies showing that patients receiving three doses of MDMA bested placebo at reducing symptoms of PTSD as measured by a severity score.
MAPS MDMA Research: Transforming PTSD Treatment
Aug 22, 2024 · Founded in 1986 by Rick Doblin, MAPS has tirelessly worked to investigate the therapeutic potential of psychedelics, with a particular focus on MDMA-assisted therapy for post-traumatic stress disorder (PTSD).
MAPS PBC Submits NDA to the FDA for MDMA-Assisted Therapy …
Dec 12, 2023 · An FDA approval of 3,4-Methylenedioxy-methamphetamine (MDMA)–assisted therapy would require the Drug Enforcement Administration to reschedule MDMA in acknowledgement of its medical use, making it available for prescription medical use.